Cannara Biotech Reports Fourth Quarter and 2023 Fiscal Year Results: Record Growth and Profitability Continues

December 7, 2023

Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022

Sequentially, Q4 showed significant growth over Q3 2023 with higher net revenues by 15%, operating income by 36%, Adjusted EBITDA by 26% and net income by 58%

Read more at prnewswire.com

Related news for (LOVFF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.